Skip to main content

Articles

Page 28 of 36

  1. Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positr...

    Authors: Marissa D. Zwan, Femke H. Bouwman, Elles Konijnenberg, Wiesje M. van der Flier, Adriaan A. Lammertsma, Frans R. J. Verhey, Pauline Aalten, Bart N. M. van Berckel and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2017 9:2
    Content type: Research Published on:

  2. Accumulation of hyperphosphorylated tau protein is a histopathological hallmark of Alzheimer’s disease (AD) and related tauopathies. Currently, there is no effective treatment available for these progressive n...

    Authors: Chun-ling Dai, Yunn Chyn Tung, Fei Liu, Cheng-Xin Gong and Khalid Iqbal
    Citation: Alzheimer's Research & Therapy 2017 9:1
    Content type: Research Published on:

  3. The sortilin-related receptor 1 (SORL1) gene, regulating the trafficking and recycling of amyloid precursor protein, has been related to Alzheimer’s disease (AD) and mild cognitive impairment (MCI). The aim of th...

    Authors: Cheng-Ta Chou, Yi-Chu Liao, Wei-Ju Lee, Shuu-Jiun Wang and Jong-Ling Fuh
    Citation: Alzheimer's Research & Therapy 2016 8:53
    Content type: Research Published on:

  4. Amyloid-β 1–42 peptide (Aβ1–42) is associated with plaque formation in the brain of patients with Alzheimer’s disease (AD). Pharmacodynamic studies of AD therapeutics that lower the concentrations of Aβ1–42 in pe...

    Authors: Linan Song, D. Richard Lachno, David Hanlon, Adam Shepro, Andreas Jeromin, Dipika Gemani, Jayne A. Talbot, Margaret M. Racke, Jeffrey L. Dage and Robert A. Dean
    Citation: Alzheimer's Research & Therapy 2016 8:58
    Content type: Research Published on:

  5. Hyperphosphorylation and aggregation of tau protein are the pathological hallmarks of Alzheimer’s disease and related tauopathies. We previously demonstrated that the microglial activation induces tau hyperpho...

    Authors: Nicole Maphis, Shanya Jiang, Guixiang Xu, Olga N. Kokiko-Cochran, Saktimayee M. Roy, Linda J. Van Eldik, D. Martin Watterson, Bruce T. Lamb and Kiran Bhaskar
    Citation: Alzheimer's Research & Therapy 2016 8:54
    Content type: Research Published on:

  6. Accumulating evidence implicates the neuroendocrine immunomodulation (NIM) network in the physiopathological mechanism of Alzheimer’s disease (AD). Notably, we previously revealed that the NIM network is dysre...

    Authors: Jian-Hui Wang, Xi Lei, Xiao-Rui Cheng, Xiao-Rui Zhang, Gang Liu, Jun-Ping Cheng, Yi-Ran Xu, Ju Zeng, Wen-Xia Zhou and Yong-Xiang Zhang
    Citation: Alzheimer's Research & Therapy 2016 8:57
    Content type: Research Published on:

  7. It is unknown whether older adults in the United States would be willing to take a test predictive of future Alzheimer’s disease, or whether testing would change behavior. Using a nationally representative sam...

    Authors: Meera Sheffrin, Irena Stijacic Cenzer and Michael A. Steinman
    Citation: Alzheimer's Research & Therapy 2016 8:55
    Content type: Research Published on:

  8. According to new diagnostic guidelines for Alzheimer’s disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD deme...

    Authors: Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz and Robert Perneczky
    Citation: Alzheimer's Research & Therapy 2016 8:51
    Content type: Research Published on:

  9. Frontotemporal dementia is an increasingly studied disease, the underlying functional impairments on a neurobiological level of which have not been fully understood. Patients with the behavioral-subtype fronto...

    Authors: Florian G. Metzger, Betti Schopp, Florian B. Haeussinger, Katja Dehnen, Matthis Synofzik, Andreas J. Fallgatter and Ann-Christine Ehlis
    Citation: Alzheimer's Research & Therapy 2016 8:56
    Content type: Research Published on:

  10. Progressive and relatively circumscribed loss of semantic knowledge, referred to as semantic dementia (SD) which falls under the broader umbrella of frontotemporal dementia, was officially identified as a clin...

    Authors: Ramon Landin-Romero, Rachel Tan, John R. Hodges and Fiona Kumfor
    Citation: Alzheimer's Research & Therapy 2016 8:52
    Content type: Review Published on:

  11. Mild cognitive impairment (MCI) is a syndrome that disrupts an individual’s cognitive function but preserves activities of daily living. MCI is thought to be a prodromal stage of dementia, which disrupts patie...

    Authors: Kyongsik Yun, In-Uk Song and Yong-An Chung
    Citation: Alzheimer's Research & Therapy 2016 8:49
    Content type: Research Published on:

  12. Hyperactivity of the classical axis of the renin-angiotensin system (RAS), mediated by angiotensin II (Ang II) activation of the angiotensin II type 1 receptor (AT1R), is implicated in the pathogenesis of Alzh...

    Authors: Patrick Gavin Kehoe, Steffenny Wong, Noura AL Mulhim, Laura Elyse Palmer and J. Scott Miners
    Citation: Alzheimer's Research & Therapy 2016 8:50
    Content type: Research Published on:

  13. In a research study, to give a comprehensive evaluation of the impact of interventions, the outcome measures should reflect the lived experience of the condition. In dementia studies, this necessitates the use...

    Authors: Jennifer Kirsty Harrison, Anna H. Noel-Storr, Nele Demeyere, Emma L. Reynish and Terry J. Quinn
    Citation: Alzheimer's Research & Therapy 2016 8:48
    Content type: Research Published on:

  14. In this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using different costing approaches to highlight methodological issues.

    Authors: Anders Wimo, Linus Jönsson, Laura Fratiglioni, Per Olof Sandman, Anders Gustavsson, Anders Sköldunger and Lennarth Johansson
    Citation: Alzheimer's Research & Therapy 2016 8:59
    Content type: Research Published on:

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2017 9:12

  15. A large, prospective, 2-year, randomized study in patients with mild-to-moderate Alzheimer’s disease or mixed dementia demonstrated reductions in mortality and cognitive/functional decline in galantamine-treat...

    Authors: Klaus Hager, Alan S. Baseman, Jeffrey S. Nye, H. Robert Brashear, John Han, Mary Sano, Bonnie Davis and Henry M. Richards
    Citation: Alzheimer's Research & Therapy 2016 8:47
    Content type: Research Published on:

  16. Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be ...

    Authors: S. A. S. A. Bemelmans, K. Tromp, E. M. Bunnik, R. J. Milne, S. Badger, C. Brayne, M. H. Schermer and E. Richard
    Citation: Alzheimer's Research & Therapy 2016 8:46
    Content type: Research Published on:

  18. Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subje...

    Authors: Laura M. Gault, Robert A. Lenz, Craig W. Ritchie, Andreas Meier, Ahmed A. Othman, Qi Tang, Scott Berry, Yili Pritchett and Weining Z. Robieson
    Citation: Alzheimer's Research & Therapy 2016 8:44
    Content type: Research Published on:

  19. There is a need to investigate biomarkers that are indicative of the progression of dementia in ethnic patient populations. The disparity of information in these populations has been the focus of many clinical...

    Authors: Rinko Grewal, Mona Haghighi, Shuai Huang, Amanda G. Smith, Chuanhai Cao, Xiaoyang Lin, Daniel C. Lee, Nancy Teten, Angela M. Hill and Maj-Linda B. Selenica
    Citation: Alzheimer's Research & Therapy 2016 8:43
    Content type: Research Published on:

  20. Mild parkinsonian signs (MPS) are common in older people and are associated with an increased risk of different neurodegenerative diseases. This study prospectively evaluates the longitudinal course of cogniti...

    Authors: Stefanie Lerche, Kathrin Brockmann, Andrea Pilotto, Isabel Wurster, Ulrike Sünkel, Markus A. Hobert, Anna-Katharina von Thaler, Claudia Schulte, Erik Stoops, Hugo Vanderstichele, Victor Herbst, Britta Brix, Gerhard W. Eschweiler, Florian G. Metzger, Walter Maetzler and Daniela Berg
    Citation: Alzheimer's Research & Therapy 2016 8:42
    Content type: Research Published on:

  21. Synaptic degeneration is a central pathogenic event in Alzheimer’s disease that occurs early during the course of disease and correlates with cognitive symptoms. The pre-synaptic vesicle protein synaptotagmin-...

    Authors: Annika Öhrfelt, Ann Brinkmalm, Julien Dumurgier, Gunnar Brinkmalm, Oskar Hansson, Henrik Zetterberg, Elodie Bouaziz-Amar, Jacques Hugon, Claire Paquet and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2016 8:41
    Content type: Research Published on:

  22. The recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau path...

    Authors: Laure Saint-Aubert, Ove Almkvist, Konstantinos Chiotis, Rita Almeida, Anders Wall and Agneta Nordberg
    Citation: Alzheimer's Research & Therapy 2016 8:38
    Content type: Research Published on:

  23. The global impact of Alzheimer’s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively t...

    Authors: Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. Jack Jr, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2016 8:39
    Content type: Review Published on:

  24. Amyloid-beta (Aβ) plays a key role in Alzheimer’s disease (AD) pathogenesis, and soluble Aβ oligomers are more cytotoxic than Aβ fibrils. Recent evidence suggests that Notch signaling is affected by AD and oth...

    Authors: Shuman Zhang, Pan Wang, Lili Ren, Chunli Hu and Jing Bi
    Citation: Alzheimer's Research & Therapy 2016 8:40
    Content type: Research Published on:

  25. The annual Alzheimer’s Research UK (ARUK) Conference was hosted by the Manchester and North West Network Centre on March 8–9, 2016. In this report, we provide a summary of the research presented.

    Authors: Rosa M. Sancho, Carla J. Cox, Laura E. Phipps and Simon H. Ridley
    Citation: Alzheimer's Research & Therapy 2016 8:35
    Content type: Meeting report Published on:

  26. Gamma-hydroxybutyrate (GHB or XyremR) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in...

    Authors: Michel Maitre, Christian Klein and Ayikoe G. Mensah-Nyagan
    Citation: Alzheimer's Research & Therapy 2016 8:37
    Content type: Viewpoint Published on:

  27. Targeting the expression of genes has emerged as a potentially viable therapeutic approach to human disease. In Alzheimer’s disease, therapies that silence the expression of tau could be a viable strategy to s...

    Authors: Susan Fromholt, Christian Reitano, Hilda Brown, Jada Lewis and David R. Borchelt
    Citation: Alzheimer's Research & Therapy 2016 8:36
    Content type: Research Published on:

  28. Familial Alzheimer’s disease (FAD) is caused by mutations in the amyloid precursor protein (APP) or presenilin (PS). Most PS mutations, which account for the majority of FAD cases, lead to an increased ratio o...

    Authors: Jean-François Blain, Matthew G. Bursavich, Emily A. Freeman, Lori A. Hrdlicka, Hilliary E. Hodgdon, Ting Chen, Don E. Costa, Bryce A. Harrison, Sudarshan Kapadnis, Deirdre A. Murphy, Scott Nolan, Zhiming Tu, Cuyue Tang, Duane A. Burnett, Holger Patzke and Gerhard Koenig
    Citation: Alzheimer's Research & Therapy 2016 8:34
    Content type: Research Published on:

  29. Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline...

    Authors: Penny A. Dacks, Joshua J. Armstrong, Stephen K. Brannan, Aaron J. Carman, Allan M. Green, M. Sue Kirkman, Lawrence R. Krakoff, Lewis H. Kuller, Lenore J. Launer, Simon Lovestone, Elizabeth Merikle, Peter J. Neumann, Kenneth Rockwood, Diana W. Shineman, Richard G. Stefanacci, Priscilla Velentgas…
    Citation: Alzheimer's Research & Therapy 2016 8:33
    Content type: Review Published on:

  30. The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research...

    Authors: Rita Banzi, Paolo Camaioni, Mauro Tettamanti, Vittorio Bertele’ and Ugo Lucca
    Citation: Alzheimer's Research & Therapy 2016 8:32
    Content type: Research Published on:

  31. The aim of this volumetric study was to explore the neuroanatomical correlates of the Free and Cued Selective Reminding Test (FCSRT) and the Delayed Matching-to-Sample—48 items (DMS-48), two tests widely used ...

    Authors: N. Philippi, V. Noblet, E. Duron, B. Cretin, C. Boully, I. Wisniewski, M. L. Seux, C. Martin-Hunyadi, E. Chaussade, C. Demuynck, S. Kremer, S. Lehéricy, D. Gounot, J. P. Armspach, O. Hanon and F. Blanc
    Citation: Alzheimer's Research & Therapy 2016 8:26
    Content type: Research Published on:

  32. Current projections of the scale of the coming dementia epidemic assume that the age- and sex-specific prevalence of dementia will not vary over time, and that population ageing alone (increasing the number of...

    Authors: Martin Prince, Gemma-Claire Ali, Maëlenn Guerchet, A. Matthew Prina, Emiliano Albanese and Yu-Tzu Wu
    Citation: Alzheimer's Research & Therapy 2016 8:23
    Content type: Research Published on:

  33. Little is known about the patterns of brain atrophy in prodromal dementia with Lewy bodies (pro-DLB).

    Authors: Frederic Blanc, Sean J. Colloby, Benjamin Cretin, Paulo Loureiro de Sousa, Catherine Demuynck, John T. O’Brien, Catherine Martin-Hunyadi, Ian McKeith, Nathalie Philippi and John-Paul Taylor
    Citation: Alzheimer's Research & Therapy 2016 8:31
    Content type: Research Published on:

  34. We aimed to describe specific changes in brain perfusion in patients with dementia with Lewy bodies (DLB) at both the prodromal (also called mild cognitive impairment) and mild dementia stages, relative to pat...

    Authors: Daniel Roquet, Marion Sourty, Anne Botzung, Jean-Paul Armspach and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2016 8:29
    Content type: Research Published on:

  35. Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer’s disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been t...

    Authors: Helga Eyjolfsdottir, Maria Eriksdotter, Bengt Linderoth, Göran Lind, Bengt Juliusson, Philip Kusk, Ove Almkvist, Niels Andreasen, Kaj Blennow, Daniel Ferreira, Eric Westman, Inger Nennesmo, Azadeh Karami, Taher Darreh-Shori, Ahmadul Kadir, Agneta Nordberg…
    Citation: Alzheimer's Research & Therapy 2016 8:30
    Content type: Research Published on:

  37. Apolipoprotein E (APOE) ɛ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer’s disease (AD). The results of several studies indicate an interaction between docosa...

    Authors: Hussein N. Yassine, Varun Rawat, Wendy J. Mack, Joseph F. Quinn, Karin Yurko-Mauro, Eileen Bailey-Hall, Paul S. Aisen, Helena C. Chui and Lon S. Schneider
    Citation: Alzheimer's Research & Therapy 2016 8:25
    Content type: Research Published on:

  38. Immunotherapy with monoclonal antibodies that target amyloid beta has been under investigation as a treatment for patients with Alzheimer’s disease (AD). The 3000 and 3001 phase 3 clinical studies of intraveno...

    Authors: Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan, Lisa Hua, Prisca Lucas, Scot Styren, Lingfeng Yang, David Li, Ronald S. Black, H. Robert Brashear and Thomas McRae
    Citation: Alzheimer's Research & Therapy 2016 8:24
    Content type: Research Published on:

  39. Affective and psychotic disorders are mental or behavioural patterns resulting in an inability to cope with life’s ordinary demands and routines. These conditions can be a prodromal event of Alzheimer’s diseas...

    Authors: Claire Paquet, Eloi Magnin, David Wallon, Anne-Cécile Troussière, Julien Dumurgier, Alain Jager, Frank Bellivier, Elodie Bouaziz-Amar, Frédéric Blanc, Emilie Beaufils, Carole Miguet-Alfonsi, Muriel Quillard, Susanna Schraen, Florence Pasquier, Didier Hannequin, Philippe Robert…
    Citation: Alzheimer's Research & Therapy 2016 8:27
    Content type: Research Published on:

  40. Increased concentrations of cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau, as well as decreased amyloid-β 42 peptide, are biomarkers of Alzheimer’s disease (AD) pathology, but few studies ...

    Authors: Malin Degerman Gunnarsson, Martin Ingelsson, Kaj Blennow, Hans Basun, Lars Lannfelt and Lena Kilander
    Citation: Alzheimer's Research & Therapy 2016 8:22
    Content type: Research Published on:

  41. A growing body of evidence suggests that microRNAs (miRNAs) are involved in Alzheimer’s disease (AD) and that some disease-associated genetic variants are located within miRNA binding sites. In the present stu...

    Authors: Charlotte Delay, Benjamin Grenier-Boley, Philippe Amouyel, Julie Dumont and Jean-Charles Lambert
    Citation: Alzheimer's Research & Therapy 2016 8:20
    Content type: Research Published on:

  42. Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling res...

    Authors: Bianca Van Broeck, Maarten Timmers, Steven Ramael, Jennifer Bogert, Leslie M. Shaw, Marc Mercken, John Slemmon, Luc Van Nueten, Sebastiaan Engelborghs and Johannes Rolf Streffer
    Citation: Alzheimer's Research & Therapy 2016 8:21
    Content type: Research Published on:

  43. Over the past two decades, the APOE gene and its polymorphisms have been among the most studied risk factors of Alzheimer disease (AD) development; yet, there are discrepancies between various studies regarding t...

    Authors: Anna Limon-Sztencel, Beata S. Lipska-Ziętkiewicz, Magdalena Chmara, Bartosz Wasag, Leszek Bidzan, Beata R. Godlewska and Janusz Limon
    Citation: Alzheimer's Research & Therapy 2016 8:19
    Content type: Research Published on:

  44. Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD).

    Authors: Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth…
    Citation: Alzheimer's Research & Therapy 2016 8:18
    Content type: Research Published on:

  45. Alzheimer’s disease (AD) neuropathology is associated with neuroinflammation, but there are few useful biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been...

    Authors: Kristi Henjum, Ina S. Almdahl, Vibeke Årskog, Lennart Minthon, Oskar Hansson, Tormod Fladby and Lars N. G. Nilsson
    Citation: Alzheimer's Research & Therapy 2016 8:17
    Content type: Research Published on:

  47. CRTC1 (CREB regulated transcription coactivator 1) gene plays a role in synaptic plasticity, learning and long-term memory formation in the hippocampus. Recently, CRTC1 has been shown ...

    Authors: Maite Mendioroz, Naiara Celarain, Miren Altuna, Javier Sánchez-Ruiz de Gordoa, María Victoria Zelaya, Miren Roldán, Idoya Rubio, Rosa Larumbe, María Elena Erro, Iván Méndez and Carmen Echávarri
    Citation: Alzheimer's Research & Therapy 2016 8:15
    Content type: Research Published on:

  48. Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofi...

    Authors: Veronika Logovinsky, Andrew Satlin, Robert Lai, Chad Swanson, June Kaplow, Gunilla Osswald, Hans Basun and Lars Lannfelt
    Citation: Alzheimer's Research & Therapy 2016 8:14
    Content type: Research Published on:

  49. The purpose of this study was to assess the efficacy of transcranial direct current stimulation (tDCS) on verbal memory function in patients with Alzheimer’s disease.

    Authors: Martin Bystad, Ole Grønli, Ingrid Daae Rasmussen, Nina Gundersen, Lene Nordvang, Henrik Wang-Iversen and Per M. Aslaksen
    Citation: Alzheimer's Research & Therapy 2016 8:13
    Content type: Research Published on:

  50. Theory of mind (ToM) refers to the ability to attribute mental states, thoughts (cognitive component) or feelings (affective component) to others. This function has been studied in man...

    Authors: Camille Heitz, Vincent Noblet, Clélie Phillipps, Benjamin Cretin, Natacha Vogt, Nathalie Philippi, Jennifer Kemp, Xavier de Petigny, Mathias Bilger, Catherine Demuynck, Catherine Martin-Hunyadi, Jean-Paul Armspach and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2016 8:10
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193